Cancer-associated superficial vein thrombosis: clinical outcomes and management
Authors:
- Adrian Joseph Michel BaileyABAdrian Joseph Michel Bailey
- Owen Dan LuoOLOwen Dan Luo
- Phil Stephen WellsPWPhil Stephen Wells
Open Access
- 16 April 2026
- journal article
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (s1)
Abstract
Venous thromboembolism (VTE) is a major cause of morbidity and noncancer mortality in patients with active malignancy, and management frameworks for cancer-associated deep vein thrombosis (DVT) and pulmonary embolism (PE) are well developed. In contrast, there exists controversy in the management of isolated superficial vein thrombosis (iSVT) in patients with active malignancies, as the guideline recommended treatment regimens for iSVT are based on randomized trials that largely excluded patients with active cancer, Furthermore, patients with cancer have a higher risk of bleeding and thrombosis complicating anticoagulant management. This review synthesizes evidence on outcomes and management of cancer-associated iSVT. The evidence indicates there is a high rate of subsequent VTE incidence after cancer-associated iSVT despite anticoagulation, and comparisons of patients with active malignancy to noncancer- associated iSVT demonstrated a substantially higher VTE risk with cancer, with low rates of major bleeding. This suggests that patients with cancer-associated iSVT may benefit from higher doses of anticoagulation and/or extended therapy. However, the data suffers from heterogeneity and limited numbers emphasizing the need for randomized controlled trials to assess the optimal anticoagulant intensity/duration for patients with cancer-associated iSVT.Keywords
This publication has 30 references indexed in Scilit:
- The incidence and risk of venous thromboembolism in patients with active malignancy and isolated superficial venous thrombosis: a systematic review and meta-analysis (the IROVAM–iSVT review)Journal of Thrombosis and Haemostasis, 2025
- Superficial vein thrombosis and its relationship with malignancies: a prospective observational studyJournal of Thrombosis and Thrombolysis, 2024
- Antithrombotic Therapy for VTE DiseaseChest, 2024
- Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysisAmerican Journal of Hematology, 2024
- A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosisJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2023
- Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapyJournal of Thrombosis and Haemostasis, 2023
- Prevalence of cancer in patients with superficial vein thrombosis and its clinical importanceJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2022
- Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective studyJournal of Thrombosis and Thrombolysis, 2016
- A Pilot Randomized Double-blind Comparison of a Low-Molecular-Weight Heparin, a Nonsteroidal Anti-inflammatory Agent, and Placebo in the Treatment of Superficial Vein ThrombosisArchives of internal medicine (1960), 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986